Monte Rosa Therapeutics Inc GLUE.OQ GLUE.O is expected to show a rise in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025
The Boston Massachusetts-based company is expected to report a 1,239.3% increase in revenue to $14.25 million from $1.06 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Monte Rosa Therapeutics Inc is for a loss of 34 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Monte Rosa Therapeutics Inc is $16.50, above its last closing price of $4.97.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.02 | 0.23 | Beat | 1,100 | |
Sep. 30 2024 | -0.46 | -0.49 | -0.29 | Beat | 40.4 |
Jun. 30 2024 | -0.53 | -0.54 | -0.43 | Beat | 20.4 |
Mar. 31 2024 | -0.57 | -0.57 | -0.53 | Beat | 7.5 |
Dec. 31 2023 | -0.30 | -0.33 | -0.58 | Missed | -73.3 |
Sep. 30 2023 | -0.72 | -0.72 | -0.70 | Beat | 3.3 |
Jun. 30 2023 | -0.69 | -0.70 | -0.71 | Missed | -1.4 |
Mar. 31 2023 | -0.68 | -0.68 | -0.65 | Beat | 4.3 |
This summary was machine generated May 5 at 12:46 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。